A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate the mechanism of therapeutic response and resistance to FGFR inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Notes
-
Hannover, Medizinische Hochschule Hannover, Dissertation, 2021
- Keyword
-
Bile ducts--Cancer
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Bibliothek der Medizinischen Hochschule Hannover
- (when)
-
2021
- Creator
- Contributor
- DOI
-
10.26068/mhhrpm/20210426-007
- URN
-
urn:nbn:de:101:1-2021070813102614159734
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kendre, Gajanan Bhujangrao
- Vogel, Arndt
- Lehmann, Ulrich
- Klinik für Gastroenterologie, Hepatologie und Endokrinologie
- Bibliothek der Medizinischen Hochschule Hannover
Time of origin
- 2021
Other Objects (12)
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Correction to: The focus clinical research in intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma with a liver abscess due to hepatic actinomycosis
Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma
Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate SUMOylation
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Correction to: The focus clinical research in intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma with a liver abscess due to hepatic actinomycosis
Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma
Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate SUMOylation
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Correction to: The focus clinical research in intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma with a liver abscess due to hepatic actinomycosis
Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma
The focus clinical research in intrahepatic cholangiocarcinoma
Prognostic factors in patients with intrahepatic cholangiocarcinoma
Differential enrichment of H3K9me3 in intrahepatic cholangiocarcinoma